我国与GPA成员方及印度制剂产业外贸竞争力比较研究  

Trade competitiveness analysis of Chinese pharmaceutical industry:Comparing with GPA members and India

作　　者：邹珺[1] 

机构地区：[1]卫生部卫生发展研究中心,北京100191

出　　处：《中国卫生政策研究》2011年第6期39-44,共6页Chinese Journal of Health Policy

摘　　要：产业的外贸竞争力决定其国际市场份额。对我国与GPA成员方以及印度的制剂产业外贸竞争力比较研究发现:我国制剂出口的国际市场占有率不足1%,贸易竞争优势指数为负值,显示性比较优势指数长期处于较低水平,制药产业外贸竞争力不仅与GPA成员相差悬殊,甚至明显落后于印度。因此,在我国制剂产业外贸竞争力取得长足进步之前,加入GPA难以改变目前我国单方面开放医药市场的现状,对我国制药产业很可能"弊大于利"。我国医药产业应借推行新版GMP和落实自主创新方略等政策的机会,加快企业"走出去"的步伐,争取在加入GPA之前成为真正的制药强国。Industry trade competitiveness determines the international market share.The comparative analysis with GPA members and India reveals that Chinese trade competitiveness of pharmaceutical industry is much lower than GPA members and even remarkably lower than India：Export market share is not more than 1%,Trade Special Coefficient Index（TC） is negative,and Revealed Comparative Advantage Index（RCA） maintains very small.Therefore,before substantial changes have happened in Chinese pharmaceutical industry,joining the GPA could not help to changes the present unilateral openness of pharmaceutical products market and would have more disadvantages than advantages.Chinese pharmaceutical industry should capture the opportunity in the process of implementing the new GMP and the independent creation and innovation strategy,speed up the internationalization pace of Chinese pharmaceutical enterprise,and endeavor to become a real strong country in pharmaceutical industry before we join the GPA.

关 键 词：制药产业 政府采购协议 外贸竞争力 贸易竞争优势指数 显示性比较优势指数 

分 类 号：R951[医药卫生—药学]